Scilex Holding (SCLX) Total Liabilities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Total Liabilities of $547.7 million for Q1 2026, up 88.56% year-over-year from $290.5 million in Q1 2025, and down 5.03% quarter-over-quarter from $576.7 million in Q4 2025.
Scilex Holding (SCLX) Total Liabilities (2020 - 2026) Analysis & Trends
Scilex Holding's Total Liabilities history runs 7 years deep, the most recent figure standing at $547.7 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 88.56% year-over-year to $547.7 million; the TTM figure through Mar 2026 stood at $547.7 million (up 88.56% YoY), while the FY2025 annual figure was $576.7 million, up 101.94% from the prior year.
- Total Liabilities for Q1 2026 stood at $547.7 million, down from $576.7 million in the prior quarter.
- The five-year high for Total Liabilities was $576.7 million in Q4 2025, with the low at $11.1 million in Q1 2022.
- The 5-year median for Total Liabilities is $281.0 million (2024), against an average of $249.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities sank 83.34% in 2022, then surged 1898.54% in 2023.
- Scilex Holding's Total Liabilities stood at $50.3 million in 2022, then surged by 445.35% to $274.2 million in 2023, then rose by 4.14% to $285.6 million in 2024, then surged by 101.94% to $576.7 million in 2025, then declined by 5.03% to $547.7 million in 2026.
- Business Quant data shows SCLX's Total Liabilities at $547.7 million in Q1 2026, $576.7 million in Q4 2025, and $455.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Scilex Holding | 39.35 Mn | -73.44 Mn | 3.97 Mn | 564.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 547.71 Mn |
| Dec 31, 2025 | 576.73 Mn |
| Sep 30, 2025 | 455.60 Mn |
| Jun 30, 2025 | 332.74 Mn |
| Mar 31, 2025 | 290.46 Mn |
| Dec 31, 2024 | 285.59 Mn |
| Sep 30, 2024 | 311.75 Mn |
| Jun 30, 2024 | 319.24 Mn |
| Mar 31, 2024 | 281.03 Mn |
| Dec 31, 2023 | 274.25 Mn |
| Sep 30, 2023 | 243.20 Mn |
| Jun 30, 2023 | 116.05 Mn |
| Mar 31, 2023 | 74.98 Mn |
| Dec 31, 2022 | 50.29 Mn |
| Sep 30, 2022 | 12.17 Mn |
| Jun 30, 2022 | 52.88 Mn |
| Mar 31, 2022 | 11.10 Mn |
| Dec 31, 2021 | 301.81 Mn |
| Sep 30, 2021 | 10.09 Mn |
| Jun 30, 2021 | 8.90 Mn |